dc.contributor.author |
Romero-Gómez, Manuel |
dc.contributor.author |
Turnes, Juan |
dc.contributor.author |
Ampuero, Javier |
dc.contributor.author |
Oyagüez, Itziar |
dc.contributor.author |
Cuenca, Beatriz |
dc.contributor.author |
Gonzalez-García, Juan |
dc.contributor.author |
Muñoz-Molina, Belén |
dc.contributor.author |
Aguilar, Rocío |
dc.contributor.author |
Leal, Sandra |
dc.contributor.author |
Planas Vilà, Ramon |
dc.contributor.author |
Garcia-Samaniego, Javier |
dc.contributor.author |
Diago, Moises |
dc.contributor.author |
Crespo García, Javier |
dc.contributor.author |
Calleja, Jose Luis |
dc.contributor.author |
Casado, Miguel Ángel |
dc.contributor.author |
Solà Lamoglia, Ricard |
dc.date |
2015 |
dc.identifier |
https://ddd.uab.cat/record/157966 |
dc.identifier |
urn:10.1371/journal.pone.0122613 |
dc.identifier |
urn:oai:ddd.uab.cat:157966 |
dc.identifier |
urn:pmid:25826755 |
dc.identifier |
urn:scopus_id:84926393490 |
dc.identifier |
urn:wos_id:000352084800084 |
dc.identifier |
urn:altmetric_id:3948300 |
dc.identifier |
urn:pmc-uid:4426774 |
dc.identifier |
urn:pmcid:PMC4426774 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:4426774 |
dc.identifier |
urn:oai:egreta.uab.cat:publications/aa773c07-4081-45f3-adc0-21e68080f043 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
PloS one ; Vol. 10, No 3 (March 2015), p. e0122613 |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by/3.0/ |
dc.subject |
Fibrosis |
dc.subject |
Protease inhibitor therapy |
dc.subject |
Viral load |
dc.subject |
Hepatitis C |
dc.subject |
Hepatitis C virus |
dc.subject |
Variant genotypes |
dc.subject |
Co-infections |
dc.subject |
HIV |
dc.title |
Prediction of week 4 virological response in hepatitis C for making decision on triple therapy : the Optim study |
dc.type |
Article |
dc.description.abstract |
Background: Virological response to peginterferon + ribavirin (P+R) at week 4 can predict sustained virological response (SVR). While patients with rapid virological response (RVR) do not require triple therapy, patients with a decline <1log10 IU/ml HCVRNA (D1L) should have treatment discontinued due to low SVR rate. Aim: To develop a tool to predict first 4 weeks' viral response in patients with hepatitis C genotype 1&4 treated with P+R. Methods: In this prospective and multicenter study, HCV mono-infected (n=538) and HCV/HIV co-infected (n=186) patients were included. To develop and validate a prognostic tool to detect RVR and D1L, we segregated the patients as an estimation cohort (to construct the model) and a validation cohort (to validate the model). Results: D1L was reached in 509 (80.2%) and RVR in 148 (22.5%) patients. Multivariate analyses demonstrated that HIV co-infection, Forns' index, LVL, IL28B-CC and Genotype-1 were independently related to RVR as well as D1L. Diagnostic accuracy (AUROC) for D1L was: 0.81 (95%CI: 0.76 ̶ 0.86) in the estimation cohort and 0.71 (95%CI: 0.62 ̶ 0.79) in the validation cohort; RVR prediction: AUROC 0.83 (95%CI: 0.78 ̶ 0.88) in the estimation cohort and 0.82 (95%CI: 0.76 ̶ 0.88) in the validation cohort. Cost-analysis of standard 48-week treatment indicated a saving of 30.3% if the prognostic tool is implemented. Conclusions: The combination of genetic (IL28B polymorphism) and viral genotype together with viral load, HIV co-infection and fibrosis stage defined a tool able to predict RVR and D1L at week 4. Using this tool would be a cost-saving strategy compared to universal triple therapy for hepatitis C. |